论文部分内容阅读
观察COX-2选择性抑制剂塞来西布(Celecoxib)联合外照射对5种不同恶性肿瘤细胞杀灭作用的影响,探讨塞来西布对恶性肿瘤细胞放射增敏作用的普遍性,为临床使用塞来西布作为放射增敏剂提供理论依据。选择适当浓度的COX-2选择性抑制剂塞来西布(Celecoxib)进行放射增敏实验,设置单纯放射组(R)和放射+药物(D+R)组,采用集落形成法分别检测Celecoxib对脑胶质瘤细胞株SHG-44、767,肺腺癌细胞株A549,宫颈癌细胞株HeLa,鼻咽癌细胞株CNE的放射增敏效应,并绘制细胞存活曲线。集落形成试验结果及存活曲线的相关参数显示,Celecoxib在2个胶质瘤株(SHG-44细胞、767细胞)均显示出放射增敏效应,R组和R+D组相比较,反映放射敏感性指标的SF2、D0.01、、D0、Dq均出现不同程度的下调。COX-2抑制剂Celecoxib在体外实验中可以提高多种恶性肿瘤细胞的放射敏感性。Celecoxib有可能成为治疗恶性肿瘤的放射增敏剂。
To observe the effects of COX-2 selective inhibitor Celecoxib combined with external irradiation on the killing effect of 5 different malignant tumor cells and to explore the universality of Celecoxib radiosensitizing effect on malignant tumor cells for clinical The use of Celecoxib as a radiosensitizer provides a theoretical basis. The radiosensitivity test of Celecoxib, a selective inhibitor of COX-2, was performed at a suitable concentration. The groups of radiotherapy alone (R) and radiation + medicine (D + R) were set up. Glioma cell line SHG-44,767, lung adenocarcinoma cell line A549, cervical cancer cell line HeLa, and nasopharyngeal carcinoma cell line CNE. The cell survival curve was drawn. The results of colony formation test and the related parameters of survival curve showed that Celecoxib showed radiosensitizing effect in two glioma strains (SHG-44 and 767 cells). Compared with R + D group, Celecoxib reflected radiosensitivity Sexual indicators of SF2, D0.01, D0, Dq were down to varying degrees. The COX-2 inhibitor Celecoxib can enhance the radiosensitivity of various malignant tumor cells in vitro. Celecoxib is likely to become a radiosensitizer for malignant tumors.